Teladoc Health, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-200.3M | $-1.00B | $-220.4M | $-13.66B | $-428.8M | $-485.1M | $-98.9M | $-97.1M |
| Depreciation & Amortization | — | — | — | $256.0M | $204.2M | $69.5M | $39.0M | $35.6M |
| Depreciation | $13.3M | $10.2M | $11.1M | $11.4M | $8.9M | $4.8M | $3.4M | $4.1M |
| Amortization | $350.8M | $363.4M | $325.9M | $244.6M | $195.3M | $64.7M | $35.6M | $31.5M |
| Stock-Based Compensation | $80.4M | $146.0M | $201.6M | $217.9M | $302.6M | $475.5M | $66.7M | $43.8M |
| Net Cash from Operating Activities | $294.4M | $293.7M | $350.0M | $189.3M | $194.0M | $-53.5M | $29.9M | $-4.9M |
| Investing Activities | ||||||||
| Capital Expenditures | $8.9M | $10.8M | $11.5M | $16.5M | $8.5M | $4.0M | $3.5M | $4.0M |
| Business Acquisitions | $81.9M | $0 | $0 | $0 | $78.7M | $567.4M | $11.2M | $282.4M |
| Net Cash from Investing Activities | $-266.0M | $-124.1M | $-156.3M | $-167.7M | $-73.0M | $-591.0M | $25.0M | $-257.5M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-551.7M | $8.3M | $10.9M | $6.5M | $40.9M | $859.1M | $35.1M | $645.6M |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | $285.5M | $282.9M | $338.6M | $172.8M | $185.5M | $-57.5M | $26.4M | $-8.9M |